TuHURA reports partial tumor remissions in first three patients
TuHURA reported partial tumor remissions in the first three patients in a study of IFx-2.0 with Keytruda.
TuHURA reported partial tumor remissions in the first three patients in a study of IFx-2.0 with Keytruda.